Table 2. Number of reported adverse events in association with treatment discontinuation.

Adverse event types	Sublingual zolpidem 5 mg 70 (31)		Oral zolpidem 10 mg 82 (30)		Total 152 (61)
	Continued	Discontinued	Continued	Discontinued	Continued	Discontinued
Central nervous system	23 (16)	7 (3)	19 (16)	16 (7)	42 (32)	23 (10)
Respiratory	15 (11)	0 (0)	15 (11)	0 (0)	30 (22)	0 (0)
Gastrointestinal	7 (7)	2 (1)	14 (9)	3 (3)	21 (16)	5 (4)
Neuromuscular and skeletal	10 (10)	0 (0)	4 (4)	2 (2)	14 (14)	2 (2)
Cardiovascular	2 (2)	0 (0)	1 (1)	1 (1)	3 (3)	1 (1)
Other	4 (4)	0 (0)	5 (3)	2 (2)	9 (7)	2 (2)
Total	61 (27)	9 (4)	58 (22)	24 (8)	119 (49)	33 (12)

Data presented as number of events (number of patients).

Continued = continued in the protocol; Discontinued = discontinued participation in the study under medical advice.

In the Total column, the numbers in parentheses may be higher than the total number of participants, since participants could report more than one adverse event during the study.